share_log

Wedbush Reiterates Outperform on Stoke Therapeutics, Maintains $17 Price Target

Benzinga ·  Jul 11 22:13

Wedbush analyst Laura Chico reiterates Stoke Therapeutics (NASDAQ:STOK) with a Outperform and maintains $17 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment